Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
vTv Therapeutics is a clinical-stage biotechnology company focused on developing oral small molecule drug candidates for type 2 diabetes and Alzheimer's disease. The company's lead asset, TTP399 (a hepatoselective glucokinase activator), targets type 2 diabetes with a differentiated mechanism that avoids hypoglycemia risk. With no commercial revenue, a $100M market cap, and strong cash position (9.79x current ratio), vTv is a binary clinical-stage bet trading on regulatory milestone catalysts.
vTv operates a classic clinical-stage biotech model with no current revenue generation. The company burns cash to fund clinical trials and regulatory submissions, aiming to either commercialize approved drugs independently, partner with larger pharmaceutical companies for milestone payments and royalties, or be acquired. Value creation depends entirely on successful clinical trial outcomes, FDA approval, and market adoption. The 100% gross margin reflects zero cost of goods sold (no product sales), while the -2378% operating margin shows pure R&D and administrative expense burn. The company's survival depends on capital raises, partnerships, or achieving commercialization before cash depletion.
TTP399 Phase 3 clinical trial data readouts and patient enrollment milestones
FDA regulatory submissions, interactions, and approval decisions for type 2 diabetes indication
Partnership announcements or licensing deals with major pharmaceutical companies
Cash runway updates and financing announcements (equity raises, debt facilities)
Competitive landscape changes in glucokinase activator development and diabetes drug approvals
Biotech sector sentiment and risk appetite for clinical-stage assets
Binary clinical trial risk - TTP399 failure in Phase 3 would likely result in >80% stock decline and potential company wind-down
FDA regulatory risk - even positive trial data may face approval delays or rejections based on safety concerns or efficacy thresholds
Competitive displacement risk from GLP-1 agonists (Ozempic, Mounjaro) dominating type 2 diabetes market and raising efficacy bar
Reimbursement uncertainty - payer willingness to cover novel diabetes mechanisms given existing generic options
Large-cap pharma competitors (Novo Nordisk, Eli Lilly) with superior commercial infrastructure and established diabetes franchises
Other glucokinase activator programs potentially reaching market first or showing superior efficacy/safety profiles
Rapid innovation in diabetes care (continuous glucose monitors, closed-loop insulin systems) reducing addressable patient population
Cash burn risk - negative operating cash flow requires periodic capital raises that dilute existing shareholders
Financing risk - inability to raise capital on favorable terms could force asset sales, partnerships on unfavorable economics, or bankruptcy
Going concern risk if clinical setbacks occur before securing partnership or approval - $100M market cap provides limited cushion
low - Clinical-stage biotechs are largely insulated from GDP fluctuations as they generate no revenue from economic activity. However, macro conditions indirectly affect access to capital markets for financing. During recessions, risk appetite for speculative biotech diminishes, making equity raises more dilutive. The 89% one-year return and 139% six-month return suggest momentum-driven trading rather than fundamental economic linkage.
High sensitivity through valuation multiples and discount rates. Clinical-stage biotechs are long-duration assets with cash flows (if any) years in the future. Rising rates increase the discount rate applied to potential future revenues, compressing valuations. The 5684x P/S ratio reflects extreme valuation sensitivity. Additionally, higher rates reduce speculative capital flows into high-risk biotech, tightening financing conditions. The company's minimal debt (0.01 D/E) means direct interest expense impact is negligible.
Minimal direct credit exposure given negligible debt and strong liquidity (9.79x current ratio). However, credit market conditions affect biotech financing availability. Tight credit spreads and strong high-yield markets correlate with easier access to convertible debt and venture financing for clinical-stage companies. Widening spreads signal risk-off sentiment that makes equity raises more dilutive.
momentum/speculative - The 89% one-year return and 139% six-month return attract momentum traders and biotech specialists willing to accept binary clinical trial risk. Not suitable for value or dividend investors given no earnings, no dividends, and extreme valuation multiples. Appeals to venture-style investors seeking asymmetric payoffs from FDA approval catalysts. The recent strong performance suggests retail and hedge fund speculation around clinical milestones.
high - Clinical-stage biotechs exhibit extreme volatility around trial data releases and regulatory decisions. Single-day moves of 30-50% are common on binary events. The stock's recent momentum (22.5% in three months) understates true volatility, which spikes around catalyst dates. Beta likely exceeds 2.0 relative to broader biotech indices. Options implied volatility typically elevated.
